- Biogen MS drug Plegridy OK'd; can it compete?
- Merck Serono ditches another multiple sclerosis candidate
- 4Q preview: Amgen, Biogen, BMS, Celgene, Novartis, Pfizer and Roche
- Biogen shuns Plegridy premium in favor of 'sensible' pricing
COMMENT Other Informa Comment
- INTERVIEW: Merck Serono's Belén Garijo on pricing, emerging markets and diversity
- Profile: Dr Reddy's CEO on mass exits, listening to parents & architecture
JOB OF THE WEEK Promote your job vacancy